{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,7]],"date-time":"2026-03-07T10:41:43Z","timestamp":1772880103207,"version":"3.50.1"},"reference-count":47,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,4,8]],"date-time":"2021-04-08T00:00:00Z","timestamp":1617840000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100013076","name":"National Major Science and Technology Projects of China","doi-asserted-by":"publisher","award":["2017ZX10202202-005-009"],"award-info":[{"award-number":["2017ZX10202202-005-009"]}],"id":[{"id":"10.13039\/501100013076","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Liver Research"],"published-print":{"date-parts":[[2021,6]]},"DOI":"10.1016\/j.livres.2021.04.001","type":"journal-article","created":{"date-parts":[[2021,4,21]],"date-time":"2021-04-21T00:13:27Z","timestamp":1618964007000},"page":"97-101","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Ulcerative colitis triggered by pegylated interferon alpha-2b in a patient with chronic hepatitis B: A case report and literature review"],"prefix":"10.1016","volume":"5","author":[{"given":"Zhishuo","family":"Mo","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jian","family":"Tang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zeqian","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dabiao","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dongying","family":"Xie","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peipei","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.livres.2021.04.001_bib1","author":"World Health Organization"},{"key":"10.1016\/j.livres.2021.04.001_bib2","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1016\/j.jhep.2017.03.021","article-title":"EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection","volume":"67","year":"2017","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.livres.2021.04.001_bib3","doi-asserted-by":"crossref","first-page":"1560","DOI":"10.1002\/hep.29800","article-title":"Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance","volume":"67","author":"Terrault","year":"2018","journal-title":"Hepatology"},{"key":"10.1016\/j.livres.2021.04.001_bib4","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s12072-015-9675-4","article-title":"Asian-Pacific clinical practice guidelines on the management of hepatitis B: a 2015 update","volume":"10","author":"Sarin","year":"2016","journal-title":"Hepatol Int"},{"key":"10.1016\/j.livres.2021.04.001_bib5","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1053\/j.gastro.2015.09.043","article-title":"Combination of tenofovir disoproxil fumarate and peginterferon \u03b1-2a increases loss of hepatitis B surface antigen in patients with chronic hepatitis B","volume":"150","author":"Marcellin","year":"2016","journal-title":"Gastroenterology"},{"key":"10.1016\/j.livres.2021.04.001_bib6","doi-asserted-by":"crossref","first-page":"4121","DOI":"10.1128\/AAC.00249-15","article-title":"Sequential combination therapy with pegylated interferon leads to loss of hepatitis B surface antigen and hepatitis B e antigen (HBeAg) seroconversion in HBeAg-positive chronic hepatitis B patients receiving long-term entecavir treatment","volume":"59","author":"Li","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.livres.2021.04.001_bib7","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1016\/j.jhep.2014.05.044","article-title":"Switching from entecavir to peg-IFN alfa-2a in patients with HBeAg-positive chronic hepatitis B: a randomised open-label trial (OSST trial)","volume":"61","author":"Ning","year":"2014","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.livres.2021.04.001_bib8","first-page":"25","article-title":"HBsAg loss with peg-interferon alfa-2a in hepatitis B patients with partial response to nucleos(t)ide analog: new switch study","volume":"6","author":"Hu","year":"2018","journal-title":"J\u00a0Clin Transl Hepatol"},{"key":"10.1016\/j.livres.2021.04.001_bib9","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/S0168-8278(96)80184-X","article-title":"A\u00a0survey of adverse events in 11,241 patients with chronic viral hepatitis treated with alfa interferon","volume":"24","author":"Fattovich","year":"1996","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.livres.2021.04.001_bib10","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1002\/hep.21146","article-title":"The clinical and physiological spectrum of interferon-alpha induced thyroiditis: toward a new classification","volume":"43","author":"Mandac","year":"2006","journal-title":"Hepatology"},{"key":"10.1016\/j.livres.2021.04.001_bib11","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.1002\/1529-0131(200007)43:7<1431::AID-ANR3>3.0.CO;2-E","article-title":"Current evidence for the induction of autoimmune rheumatic manifestations by cytokine therapy","volume":"43","author":"Ioannou","year":"2000","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.livres.2021.04.001_bib12","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1007\/s10067-004-1024-2","article-title":"Systemic lupus erythematosus arising during interferon-alpha therapy for cryoglobulinemic vasculitis associated with hepatitis C","volume":"24","author":"Niewold","year":"2005","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.livres.2021.04.001_bib13","doi-asserted-by":"crossref","first-page":"327","DOI":"10.2169\/internalmedicine.32.327","article-title":"Exacerbation of ulcerative colitis during alpha-interferon therapy for chronic hepatitis C","volume":"32","author":"Mitoro","year":"1993","journal-title":"Intern Med"},{"key":"10.1016\/j.livres.2021.04.001_bib14","first-page":"1293","article-title":"[Interferon induced IBD-like acute colitis--two cases of patients with chronic active hepatitis](in Japanese)","volume":"92","author":"Yamamoto","year":"1995","journal-title":"Nihon Shokakibyo Gakkai Zasshi"},{"key":"10.1016\/j.livres.2021.04.001_bib15","first-page":"1066","article-title":"[Exacerbation of ulcerative colitis and chronic hepatitis by the treatment with interferon for chronic hepatitis B](in Japanese)","volume":"92","author":"Yasumori","year":"1995","journal-title":"Nihon Shokakibyo Gakkai Zasshi"},{"key":"10.1016\/j.livres.2021.04.001_bib16","first-page":"3","article-title":"Clinical course of inflammatory bowel disease during treatment with interferon for associated chronic active hepatitis","volume":"27","author":"Cottone","year":"1995","journal-title":"Ital J Gastroenterol"},{"key":"10.1016\/j.livres.2021.04.001_bib17","first-page":"55","article-title":"Tratamiento con interfer\u00f3n alfa-2 recombinante en un paciente con hepatitis cr\u00f3nica por virus B y colitis ulcerosa [Recombinant alfa-2 interferon treatment of a patient with chronic hepatitis B and ulcerative olitis](in Spanish)","volume":"19","author":"Legaz Huidobro","year":"1996","journal-title":"Gastroenterol Hepatol"},{"key":"10.1016\/j.livres.2021.04.001_bib18","first-page":"399","volume":"89","author":"De Diego Lorenzo","year":"1997","journal-title":"Rev Esp Enferm Dig"},{"key":"10.1016\/j.livres.2021.04.001_bib19","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.1002\/ibd.21396","article-title":"Ulcerative colitis triggered by pegylated interferon alone therapy for chronic hepatitis C","volume":"17","author":"Alt\u0131nbas","year":"2011","journal-title":"Inflamm Bowel Dis"},{"key":"10.1016\/j.livres.2021.04.001_bib20","first-page":"399","article-title":"[A case of ulcerative colitis along with characteristic features on computed tomography (CT), developed by the treatment with interferon for chronic hepatitis C] (in Japanese)","volume":"98","author":"Niki","year":"2001","journal-title":"Nihon Shokakibyo Gakkai Zasshi"},{"key":"10.1016\/j.livres.2021.04.001_bib21","doi-asserted-by":"crossref","first-page":"964","DOI":"10.1016\/S0168-8278(01)00022-8","article-title":"Ulcerative colitis associated with interferon treatment for chronic hepatitis C","volume":"34","author":"Mavrogiannis","year":"2001","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.livres.2021.04.001_bib22","first-page":"680","article-title":"[A case of acute phase ulcerative colitis like colitis developed by the interferon-beta therapy for chronic hepatitis C](in Japanese)","volume":"100","author":"Awakawa","year":"2003","journal-title":"Nihon Shokakibyo Gakkai Zasshi"},{"key":"10.1016\/j.livres.2021.04.001_bib23","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1136\/gut.2004.049940","article-title":"Acute ulcerative colitis during successful interferon\/ribavirin treatment for chronic hepatitis","volume":"54","author":"Sprenger","year":"2005","journal-title":"Gut"},{"key":"10.1016\/j.livres.2021.04.001_bib24","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1097\/00042737-200511000-00015","article-title":"Onset of inflammatory bowel diseases during combined alpha-interferon and ribavirin therapy for chronic hepatitis C: report of two cases","volume":"17","author":"Villa","year":"2005","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"10.1016\/j.livres.2021.04.001_bib25","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1111\/j.1365-2036.2005.02556.x","article-title":"Is interferon-alpha therapy safe and effective for patients with chronic hepatitis C and inflammatory bowel disease? A case-control study","volume":"22","author":"Bargiggia","year":"2005","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.livres.2021.04.001_bib26","doi-asserted-by":"crossref","first-page":"1682","DOI":"10.1136\/gut.2006.105197","article-title":"A\u00a0case of exacerbation of ulcerative colitis induced by combination therapy with PEG-interferon alpha-2b and ribavirin","volume":"55","author":"Watanabe","year":"2006","journal-title":"Gut"},{"key":"10.1016\/j.livres.2021.04.001_bib27","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1159\/000112654","article-title":"Adminstration of PEG-interferon to a patient with ulcerative colitis and chronic hepatitis C correlated with reduced colonic inflammation and reversal of peripheral Th1\/Th2 ratios","volume":"1","author":"Kasahara","year":"2007","journal-title":"Case Rep Gastroenterol"},{"key":"10.1016\/j.livres.2021.04.001_bib28","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1002\/ibd.20152","article-title":"Rapid onset of ulcerative colitis after treatment with PEG-interferon plus ribavirin for chronic hepatitis C","volume":"13","author":"Tursi","year":"2007","journal-title":"Inflamm Bowel Dis"},{"key":"10.1016\/j.livres.2021.04.001_bib29","first-page":"1362","article-title":"[A case study: interferon-beta-induced remission of ulcerative colitis in a patient with type C chronic hepatitis](in Japanese)","volume":"105","author":"Miike","year":"2008","journal-title":"Nihon Shokakibyo Gakkai Zasshi"},{"key":"10.1016\/j.livres.2021.04.001_bib30","doi-asserted-by":"crossref","first-page":"1609","DOI":"10.1038\/ajg.2009.120","article-title":"Development of pouchitis with combination therapy with peg-interferon alpha-2b and ribavirin for chronic hepatitis C in a patient with ulcerative colitis who underwent pouch surgery","volume":"104","author":"Morimoto","year":"2009","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.livres.2021.04.001_bib31","doi-asserted-by":"crossref","first-page":"e194","DOI":"10.1016\/j.crohns.2012.11.001","article-title":"Diagnosis of inflammatory bowel disease in chronic hepatitis C patients treated with pegylated interferon and ribavirin: coincidence or consequence?","volume":"7","author":"Salgueiro","year":"2013","journal-title":"J\u00a0Crohns Colitis"},{"key":"10.1016\/j.livres.2021.04.001_bib32","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1136\/gutjnl-2012-302311","article-title":"Work disability in inflammatory bowel disease patients 10 years after disease onset: results from the IBSEN Study","volume":"62","author":"H\u00f8ivik","year":"2013","journal-title":"Gut"},{"key":"10.1016\/j.livres.2021.04.001_bib33","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1038\/nrgastro.2015.186","article-title":"Immunopathogenesis of IBD: current state of the art","volume":"13","author":"de Souza","year":"2016","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"10.1016\/j.livres.2021.04.001_bib34","doi-asserted-by":"crossref","first-page":"2441","DOI":"10.1111\/j.1572-0241.1999.01372.x","article-title":"Characterization of cytokine expression in the rectal mucosa of ulcerative colitis: correlation with disease activity","volume":"94","author":"Inoue","year":"1999","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.livres.2021.04.001_bib35","doi-asserted-by":"crossref","first-page":"1490","DOI":"10.1172\/JCI19836","article-title":"Nonclassical CD1d-restricted NK T cells that produce IL-13 characterize an atypical Th2 response in ulcerative colitis","volume":"113","author":"Fuss","year":"2004","journal-title":"J\u00a0Clin Invest"},{"key":"10.1016\/j.livres.2021.04.001_bib36","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1016\/j.gastro.2005.05.002","article-title":"Interleukin-13 is the key effector Th2 cytokine in ulcerative colitis that affects epithelial tight junctions, apoptosis, and cell restitution","volume":"129","author":"Heller","year":"2005","journal-title":"Gastroenterology"},{"key":"10.1016\/j.livres.2021.04.001_bib37","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.4049\/jimmunol.157.3.1261","article-title":"Disparate CD4+ lamina propria (LP) lymphokine secretion profiles in inflammatory bowel disease. Crohn\u2019s disease LP cells manifest increased secretion of IFN-gamma, whereas ulcerative colitis LP cells manifest increased secretion of IL-5","volume":"157","author":"Fuss","year":"1996","journal-title":"J\u00a0Immunol"},{"key":"10.1016\/j.livres.2021.04.001_bib38","doi-asserted-by":"crossref","first-page":"1756","DOI":"10.1016\/S0140-6736(16)32126-2","article-title":"Ulcerative colitis","volume":"389","author":"Ungaro","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.livres.2021.04.001_bib39","doi-asserted-by":"crossref","first-page":"1494","DOI":"10.1016\/S0140-6736(00)02880-4","article-title":"Onset of celiac disease during treatment with interferon for chronic hepatitis C","volume":"356","author":"Cammarota","year":"2000","journal-title":"Lancet"},{"key":"10.1016\/j.livres.2021.04.001_bib40","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/S0399-8320(05)80736-5","article-title":"Maladie de Crohn au cours du traitement de l\u2019h\u00e9patite chronique C par interf\u00e9ron et ribavirine [Crohn\u2019s disease associated with interferon and ribavirin treatment for chronic hepatitis C](in French)","volume":"29","author":"Khalil","year":"2005","journal-title":"Gastroenterol Clin Biol"},{"key":"10.1016\/j.livres.2021.04.001_bib41","doi-asserted-by":"crossref","first-page":"2201","DOI":"10.2174\/0929867023368656","article-title":"Cytokines and their antagonists as therapeutic agents","volume":"9","author":"Stevceva","year":"2002","journal-title":"Curr Med Chem"},{"key":"10.1016\/j.livres.2021.04.001_bib42","first-page":"597","article-title":"Induction of remission by interferon-alpha in patients with chronic active ulcerative colitis","volume":"7","author":"S\u00fcmer","year":"1995","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"10.1016\/j.livres.2021.04.001_bib43","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.1046\/j.1365-2036.2002.01264.x","article-title":"Induction and maintenance of clinical remission by interferon beta in patients with steroid-refractory active ulcerative colitis-an open long-term pilot trial","volume":"16","author":"Musch","year":"2002","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.livres.2021.04.001_bib44","doi-asserted-by":"crossref","first-page":"1286","DOI":"10.1136\/gut.52.9.1286","article-title":"Interferon beta-1a in ulcerative colitis: a placebo controlled, randomised, dose escalating study","volume":"52","author":"Nikolaus","year":"2003","journal-title":"Gut"},{"key":"10.1016\/j.livres.2021.04.001_bib45","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1016\/S1542-3565(05)00208-9","article-title":"Interferon-beta-1a for the treatment of steroid-refractory ulcerative colitis: a randomized, double-blind, placebo-controlled trial","volume":"3","author":"Musch","year":"2005","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.livres.2021.04.001_bib46","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1111\/j.1365-2036.2008.03778.x","article-title":"Clinical trial: a multicentre, randomized, double-blind, placebo-controlled, dose-finding, phase II study of subcutaneous interferon-beta-la in moderately active ulcerative colitis","volume":"28","author":"Pena-Rossi","year":"2008","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.livres.2021.04.001_bib47","doi-asserted-by":"crossref","first-page":"1728","DOI":"10.1136\/gut.52.12.1728","article-title":"A\u00a0randomised placebo controlled trial of pegylated interferon alpha in active ulcerative colitis","volume":"52","author":"Tilg","year":"2003","journal-title":"Gut"}],"container-title":["Liver Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2542568421000222?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2542568421000222?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T14:45:04Z","timestamp":1762872304000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2542568421000222"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6]]},"references-count":47,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2021,6]]}},"alternative-id":["S2542568421000222"],"URL":"https:\/\/doi.org\/10.1016\/j.livres.2021.04.001","relation":{},"ISSN":["2542-5684"],"issn-type":[{"value":"2542-5684","type":"print"}],"subject":[],"published":{"date-parts":[[2021,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Ulcerative colitis triggered by pegylated interferon alpha-2b in a patient with chronic hepatitis B: A case report and literature review","name":"articletitle","label":"Article Title"},{"value":"Liver Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.livres.2021.04.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 The Third Affiliated Hospital of Sun Yat-sen University. Publishing Services by Elsevier B. V. on behalf of KeAi Communications Co., Ltd.","name":"copyright","label":"Copyright"}]}}